oral ghk cu clinical trial Sublingual GHK-Cu GHK-Cu Peptide | The benefits,
Description
This dose has been extensively studied in combination with semaglutide under the investigational name CagriSema, achieving up to 22.7% weight reduction at 68 weeks in phase 3 trials [4]

The effects of GHK-Cu were also investigated in a randomized, double-blind clinical trial

You should consult your healthcare provider for breastfeeding advice related to your particular situation

This peptide blend is commonly researched alongside CJC-1295 No DAC + Ipamorelin, KPV, and GHK-Cu

Week 8 to 12: hair and deep tissue
